Purchase Order 75N93018P01222
- Not listed
- This is a firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and consumables. The contract is for service and maintenance of an Illumina MiSeq system for fiscal year 2021, with a total ceiling value of $14,070.00. The contract has no set-aside designation. Illumina has received numerous prior federal...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and reagents. The contract, valued at $12,875.00, is for sequencing services to support NIAID's research and diagnostic efforts. Illumina has previously been awarded other prime federal contracts and subcontracts by...
- This is a firm fixed price purchase order contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for maintenance on a MiSeq instrument, with a potential value of $12,875.00. Illumina has provided a range of sequencing systems, reagents, and services to support genomics research...
- This is a firm fixed price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for the provision of a MiSeq benchtop DNA sequencer system. The total ceiling value of the contract is $119,937.50, with a performance period ending on December 2, 2013. The contract does not have any set-aside designation. Illumina, a manufacturer and provider of sequencing and array-based solutions,...
- This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, for the delivery of a MiSeq System sequencer. The award does not have a set-aside designation and has a ceiling value of $95,931. Illumina has a history of providing sequencing systems and related products and services to...
- This is a firm fixed price Delivery Order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services, to Illumina, Inc. for $15,564.92. The contract provides Illumina sequencing systems, reagents, and related services to support genomic sequencing and analysis for research and diagnostic purposes. No set-aside designation was used. Illumina has previously received prime contract awards from agencies like the...
- This firm fixed-price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Illumina, Inc. for a one-year comprehensive plan to provide HiSeq 2000, cBOT, and MiSeq systems. The $100,884 contract does not include a set-aside provision. Illumina is a manufacturer of genetic sequencing and analysis instruments and reagents that have been utilized across various federal agencies, including the Centers...
- This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Illumina, Inc., a manufacturer of sequencing and genomic analysis instruments and reagents. The award, valued at $40,892.00, is for the provision of Illumina's products and services to support genomic sequencing and analysis. Illumina has previously been awarded prime federal contracts and subcontracts by various agencies like the NIH, CDC, USDA, and VA to provide...
- This is a firm fixed price delivery order contract awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract, valued at $236,856.24, is for the provision of consumables for the MiSeq sequencing instrument. The contract has no set-aside designation. Illumina has previously received...
- This is a firm fixed price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the prime contractor Illumina, Inc. for the purchase of MiSeq sequencing kits. The order, valued at $13,071, does not have a set-aside designation. Illumina is a for-profit manufacturer and provider of genetic sequencing and analysis instruments and reagents. The award supports NIAID's genomic research and diagnostics...
This is a firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Illumina, Inc., a manufacturer of genetic analysis instruments and reagents, for maintenance on a MiSeq sequencer. The potential value of the contract is $12,875.00. There was no set-aside designation for this contract. Illumina has received prior federal contract awards from agencies like the NIH, Centers for Disease Control and Prevention (CDC), and Department of Veterans Affairs (VA) for various sequencing systems, reagents, and services to support genomic research and diagnostics. Additionally, Illumina holds an Indefinite Delivery Contract with the Department of the Navy Bureau of Medicine and Surgery for sequencing supplies and services to support the Naval Medical Research Center's efforts in characterizing biological threats.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.9k | 8/30/18 |